Results 21 to 30 of about 961,854 (252)

Small Molecule‐Induced Differentiation As a Potential Therapy for Liver Cancer

Advanced Science, 2022
Despite the efficacy demonstrated by immunotherapy recently, liver cancer still remains one of the deadliest cancers, mainly due to heterogeneity of this disease. Continuous exploration of new therapeutics is therefore necessary.
Xu Zhang, Xiang‐Jie Zhu, Zhi Zhong, Jiang‐Chuan Du, Guo‐Xu Fang, Xiu‐liang Cui, Ling‐Ting Guan, Yan‐Yu Hu, Hong‐Yang Wang, Pei‐Lin Zhang   +9 more
doaj   +1 more source

Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

BMC Cancer, 2017
Background Whether perioperative blood transfusions (PBTs) adversely influence oncological outcomes for intrahepatic cholangiocarcinoma (ICC) patients after curative resection remains undetermined. Methods Of the 605 patients who underwent curative liver
Pei-Yun Zhou, Zheng Tang, Wei-Ren Liu, Meng-Xin Tian, Lei Jin, Xi-Fei Jiang, Han Wang, Chen-Yang Tao, Zhen-Bin Ding, Yuan-Fei Peng, Shuang-Jian Qiu, Zhi Dai, Jian Zhou, Jia Fan, Ying-Hong Shi   +14 more
doaj   +1 more source

Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study

Scientific Reports, 2022
Biliary tract cancer (BTC) has been inconsistently identified according to its location in epidemiological and clinical studies. This study retrospectively reviewed the treatment pattern and prognosis of BTC according to tumor location using the Korea ...
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sun-Whe Kim, Woo Jin Lee, Sang Myung Woo, Tae Hyun Kim, Young-Joo Won, Sang-Jae Park   +9 more
doaj   +1 more source

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs).
Sathathone Douangprachanh, Hyun Jin Joo, Hyeong Min Park, Nayoung Han, Hye Young Jang, Young Hwan Koh, Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Jung Won Chun   +11 more
doaj   +1 more source

Obesity and liver cancer

Annals of Hepatology, 2016
Obesity prevalence is rapidly increasing worldwide. It is associated with huge economic and health costs due to its clinical consequences, which includes increased incidence of type 2 diabetes, cardiovascular diseases, and development of different malignancies.
Saitta C., Pollicino T., Raimondo G.
openaire   +5 more sources

Liver Cancer 2.0

International Journal of Molecular Sciences, 2023
Liver cancer, specifically hepatocellular carcinoma (HCC), is a major global health concern due to its high prevalence in many countries [...]
openaire   +2 more sources

Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria [PDF]

Journal of Liver Cancer
This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications.
Hyun Yang, Soon Sun Kim, Seong Hee Kang, Jieun Kwon, Do Young Kim, Eunju Kim, Hyun Phil Shin, Jeong Il Yu, Jeong-Ju Yoo, Eileen L. Yoon, Sangheun Lee, Young Eun Chon, Janghan Jung, Jaekyung Cheon, Woosun Choi, Seul Ki Han, Ji Eun Han, Moon Haeng Hur, Hyun Woong Lee, Hyung Joon Kim   +19 more
doaj   +1 more source

Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis

Journal of Translational Medicine, 2020
Background Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3) pathway is a promising immunotherapeutic target and has synergistic effect with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1).
Mengzhou Guo, Feifei Yuan, Feng Qi, Jialei Sun, Qianwen Rao, Zhiying Zhao, Peixin Huang, Tingting Fang, Biwei Yang, Jinglin Xia   +9 more
doaj   +1 more source

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

World Journal of Surgical Oncology, 2023
Background CD73 promotes progression in several malignancies and is considered as a novel immune checkpoint. However, the function of CD73 in intrahepatic cholangiocarcinoma (ICC) remains uncertain.
Bao-Ye Sun, Zhang-Fu Yang, Zhu-Tao Wang, Gao Liu, Cheng Zhou, Jian Zhou, Jia Fan, Wei Gan, Yong Yi, Shuang-Jian Qiu   +9 more
doaj   +1 more source

SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance

Cancer Medicine, 2023
Background SQSTM1/p62 is a selective autophagy receptor that regulates multiple signaling pathways participating in the initiation and progression of tumors.
Jiafeng Chen, Zheng Gao, Xiaogang Li, Yinghong Shi, Zheng Tang, Weiren Liu, Xin Zhang, Ao Huang, Xuanming Luo, Qiang Gao, Guangyu Ding, Kang Song, Jian Zhou, Jia Fan, Xiutao Fu, Zhenbin Ding   +15 more
doaj   +1 more source